I. MODIFIED AGREEMENTS |
|||
Biotech Co.* | Biotech Co.* | Change from original agreement | Terms/Details (Date) |
| | |||
Crucell NV (the Netherlands; CRXL) | Rhein Biotech NV (the Netherlands; Neuer Markt: RBO) | Converted research collaboration into a commercial license agreement | Crucell's PER.C6 cell line will be used by Rhein for the development and manufacturing of a vaccine against Japanese encephalitis (4/10) |
Evotec OAI AG (Germany; Neuer Markt:EVT) | Vertex Pharmaceuticals Inc. (VRTX) | Extended agreement to provide drug discovery chemistry services to Vertex | The contract was extended until the end of June 2002; financial terms were not disclosed (5/15) |
InforMax Inc. (INMX) | Axcell Biosciences (subsidiary of Cytogen Corp.; CYTO) | Amended strategic alliance converting the terms from an exclusive license to a nonexclusive license | InforMax has the nonexclusive rights to market, promote and distribute AxCell's ProChart database; each party will have the right to market, distribute, promote and sublicense third-party products in the area of protein-protein interactions (5/3) |
II. TERMINATED AGREEMENTS | |||
Bioglan Pharma plc (UK; LSE:BGP) | CeNeS Pharmaceuticals plc (UK; LSE:CEN) | Terminated drug delivery and product development and license agreements | All rights under the agreements are returned to the original owners (4/2) |
Biosearch Italia SpA (Italy; Nuovo Mercato:BIO) | IntraBiotics Pharmaceuticals Inc. (IBPI) | Terminated agreement for North American development and commercialization rights to Ramoplanin for topical applications | Biosearch reacquired all rights to oral applications of the drug in May 2001; now it is regaining rights to all topical applications (5/13) |
Cambridge Antibody Technology Group plc (UK; CATG; LSE:CAT) | Drug Royalty Corp. Inc. (Canada; TSE:DRI) | Terminated royalty agreement | Cambridge Antibody elected to pay the C$14M (US$9M) termination payment to Drug Royalty through the allotment of 463,818 Cambridge Antibody ordinary shares; the decision to terminate was made after Inwest Investment Ltd. acquired Drug Royalty (5/1) |
PPD Discovery (subsidiary of PPD Inc.; PPDI) | Agouron Pharmaceuticals Inc. (unit of Pfizer Inc.) | Terminated research collaboration | PPD will regain research, development and licensing rights to targets for selectively eradicating cancer cells, following a decision by Agouron to conclude the collaboration in June (5/7) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ND = Not disclosed, reported and/or available. | |||
LSE = London Stock Echange; TSE = Toronto Stock Exchange | |||
